MCID: IMP005
MIFTS: 56

Impotence

Categories: Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Impotence

MalaCards integrated aliases for Impotence:

Name: Impotence 11 53 14
Erectile Dysfunction 11 28 53 41 14 16 71 75
Erectile Dysfunction Adverse Event 71
Sexual Impotence 11

Classifications:



External Ids:

Disease Ontology 11 DOID:1875
NCIt 49 C3133
UMLS 71 C0242350 C1961100

Summaries for Impotence

MedlinePlus: 41 Erectile dysfunction (ED) is a common type of male sexual dysfunction. It is when a man has trouble getting or keeping an erection. ED becomes more common as you get older. But it's not a natural part of aging. Some people have trouble speaking with their doctors about sex. But if you have ED, you should tell your doctor. ED can be a sign of health problems. It may mean your blood vessels are clogged. It may mean you have nerve damage from diabetes. If you don't see your doctor, these problems will go untreated. Your doctor can offer several new treatments for ED. For many men, the answer is as simple as taking a pill. Getting more exercise, losing weight, or stopping smoking may also help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Impotence, also known as erectile dysfunction, is related to vasculogenic impotence and prolactinoma, and has symptoms including angina pectoris, pelvic pain and tremor. An important gene associated with Impotence is PDE5A (Phosphodiesterase 5A), and among its related pathways/superpathways are Signal Transduction and MIF Mediated Glucocorticoid Regulation. The drugs Selegiline and Nebivolol have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, prostate and spinal cord, and related phenotypes are no effect and no effect

Disease Ontology: 11 A sexual dysfunction that is characterized by persistent or recurrent inability to achieve or to maintain an erection during sexual activity.

Wikipedia: 75 Erectile dysfunction (ED), also called impotence, is the type of sexual dysfunction in which the penis... more...

Related Diseases for Impotence

Diseases related to Impotence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 842)
# Related Disease Score Top Affiliating Genes
1 vasculogenic impotence 32.9 PDE5A ACE
2 prolactinoma 31.9 VIP TGFB1 SHBG PRL
3 lipid metabolism disorder 31.5 SHBG PDE5A NOS3 EDN1 CYP3A4 ACE
4 apnea, obstructive sleep 31.5 VEGFA NOS3 EDN1 ACE
5 arteries, anomalies of 31.5 VEGFA NOS3 EDN1 ACE
6 priapism 31.4 PDE5A NOS3 NOS2 EDN1
7 nonarteritic anterior ischemic optic neuropathy 31.3 VEGFA PDE5A NOS3 EDN1
8 hyperprolactinemia 31.2 VIP SHBG PRL
9 peyronie's disease 31.2 TGFB1 PDE5A NOS3 NOS1
10 optic nerve disease 31.1 VEGFA PDE5A EDN1 ACE
11 lipoprotein quantitative trait locus 31.1 VEGFA PDE5A NOS3 NOS2 KNG1 EDN1
12 type 2 diabetes mellitus 31.1 VEGFA TGFB1 SHBG PRL PDE5A NOS3
13 peripheral artery disease 30.9 VEGFA NOS3 ACE
14 microvascular complications of diabetes 5 30.9 VEGFA NOS3 NOS2 ACE
15 stroke, ischemic 30.8 VEGFA NOS3 EDNRA ANGPT1 ACE
16 heart disease 30.7 VEGFA TGFB1 PDE5A NOS3 NOS2 NOS1
17 hypogonadism 30.7 SHBG PRL PDE5A KLK3
18 bladder neck obstruction 30.7 PDE5A KLK3 ACE
19 systemic scleroderma 30.7 VEGFA EDNRA EDN1 ACE
20 peripheral vascular disease 30.6 VEGFA PDE5A NOS3 EDN1 ACE
21 vascular disease 30.6 VEGFA TGFB1 PDE5A NOS3 NOS2 KNG1
22 hypoactive sexual desire disorder 30.6 SHBG PRL PDE5A
23 varicocele 30.6 VEGFA SHBG PRL NOS3
24 exanthem 30.6 VEGFA CYP3A4 ACE
25 arteriosclerosis 30.5 SHBG EDNRA EDN1 ACE
26 orthostatic intolerance 30.5 NOS3 NOS2 ACE
27 peyronie disease 30.5 TGFB1 PDE5A NOS2
28 congestive heart failure 30.5 VEGFA PDE5A KNG1 EDNRA EDN1 ANGPT1
29 peripheral nervous system disease 30.5 VIP VEGFA KNG1 EDN1 CYP3A4 ACE
30 microvascular complications of diabetes 1 30.5 VEGFA EDN1 ANGPT1
31 alopecia, androgenetic, 1 30.5 SRD5A1 SHBG
32 androgenic alopecia 30.4 VEGFA SRD5A1 SHBG PRL
33 insulin-like growth factor i 30.4 VEGFA TGFB1 SHBG PRL
34 systolic heart failure 30.4 PDE5A EDN1 ACE
35 nonobstructive coronary artery disease 30.4 NOS3 EDN1 ACE
36 buerger disease 30.4 VEGFA NOS3 EDN1
37 pulmonary disease, chronic obstructive 30.4 TGFB1 PDE5A PDE4A ACE
38 diabetic angiopathy 30.4 VEGFA NOS3 EDN1
39 portal hypertension 30.4 NOS3 EDNRA EDN1
40 lung disease 30.3 VEGFA TGFB1 PDE4A EDN1 ACE
41 skin disease 30.3 VIP VEGFA SRD5A1 PDE4A KNG1 CYP3A4
42 angina pectoris 30.2 NOS3 KNG1 EDN1 ACE
43 aortic aneurysm 30.2 VEGFA TGFB1 NOS3 ACE
44 carotid stenosis 30.2 VEGFA NOS3 ACE
45 sexual health disorder 30.2 SHBG PRL PDE5A
46 migraine with or without aura 1 30.2 VIP VEGFA PRL PDE5A NOS3 NOS1
47 ischemia 30.2 VEGFA PDE5A NOS3 NOS2 NOS1 KNG1
48 prostatitis 30.2 TGFB1 PRL PDE5A KLK3
49 urethral stricture 30.2 TGFB1 PDE5A KLK3
50 body mass index quantitative trait locus 11 30.2 VEGFA SHBG PRL PDE5A NOS3 NOS1

Graphical network of the top 20 diseases related to Impotence:



Diseases related to Impotence

Symptoms & Phenotypes for Impotence

UMLS symptoms related to Impotence:


angina pectoris; pelvic pain; tremor; symptom/complaint potency (excluding p07 p08); equilibration disorder; inability to maintain erection; unable to perform sex

GenomeRNAi Phenotypes related to Impotence according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.2 ACE ANGPT1 CYP3A4 EDN1 EDNRA KCNMA1
2 no effect GR00402-S-2 10.2 ACE CYP3A4 EDN1 KCNMA1 KLK3 KNG1

MGI Mouse Phenotypes related to Impotence:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.22 ANGPT1 EDN1 EDNRA KCNMA1 NOS1 NOS2
2 homeostasis/metabolism MP:0005376 10.21 ACE ANGPT1 CYP3A4 EDN1 EDNRA KCNMA1
3 normal MP:0002873 10.19 CYP3A4 EDN1 EDNRA KLK3 NOS1 NOS3
4 renal/urinary system MP:0005367 10.16 ACE ANGPT1 EDN1 EDNRA KCNMA1 NOS1
5 muscle MP:0005369 10.13 ANGPT1 EDN1 EDNRA KCNMA1 KLK3 NOS1
6 endocrine/exocrine gland MP:0005379 10.06 ACE EDN1 EDNRA NOS1 NOS2 NOS3
7 liver/biliary system MP:0005370 10.01 ACE NOS1 NOS2 NOS3 PDE5A PRL
8 cardiovascular system MP:0005385 9.97 ACE ANGPT1 EDN1 EDNRA KCNMA1 KLK3
9 digestive/alimentary MP:0005381 9.86 EDN1 EDNRA KCNMA1 NOS1 NOS2 NOS3
10 immune system MP:0005387 9.77 ACE ANGPT1 EDNRA KCNMA1 NOS1 NOS2
11 reproductive system MP:0005389 9.36 ACE KCNMA1 NOS1 NOS2 NOS3 PDE3A

Drugs & Therapeutics for Impotence

Drugs for Impotence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 238)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9, 14611-52-0 5195 26757
2
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
3
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
4
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
5
Epitestosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 5408 10204 6013
6
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
7
Nitric Oxide Approved Phase 4 10102-43-9 145068
8
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
9
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0 21873174 65157
10
Testosterone enanthate Approved Phase 4 315-37-7 9416
11
Methyltestosterone Approved Phase 4 58-18-4 6010
12
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
13
Curcumin Approved, Investigational Phase 4 458-37-7, 84765-67-3 969516
14
Allantoin Approved Phase 4 97-59-6 204
15
Yohimbine Approved, Investigational, Vet_approved Phase 4 146-48-5 8969
16
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
17
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
18
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
19
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
20
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
21
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
22 Phosphodiesterase 5 Inhibitors Phase 4
23 Protective Agents Phase 4
24 Adrenergic Agonists Phase 4
25 Adrenergic beta-Agonists Phase 4
26 Monoamine Oxidase Inhibitors Phase 4
27 Antiparkinson Agents Phase 4
28 Neuroprotective Agents Phase 4
29 Citrate Phase 4
30 Pharmaceutical Solutions Phase 4
31 Hormones Phase 4
32 Vardenafil Dihydrochloride Phase 4
33 Neurotransmitter Agents Phase 4
34
Insulin Phase 4
35 Insulin, Globin Zinc Phase 4
36 Hypoglycemic Agents Phase 4
37 Androgens Phase 4
38 Hormone Antagonists Phase 4
39 Calcium, Dietary Phase 4
40 Anticoagulants Phase 4
41 Adrenergic Agents Phase 4
42 Angiotensin Receptor Antagonists Phase 4
43 Antihypertensive Agents Phase 4
44 Testosterone 17 beta-cypionate Phase 4
45 Adrenergic Antagonists Phase 4
46 Adrenergic alpha-Antagonists Phase 4
47 Calcineurin Inhibitors Phase 4
48 Chelating Agents Phase 4
49 Mydriatics Phase 4
50 Yohimbe Phase 4

Interventional clinical trials:

(show top 50) (show all 531)
# Name Status NCT ID Phase Drugs
1 Observational Study to Evaluate the Effect of Tadalafil 5mg Once Daily on Erectile Dysfunction and QOL in Andropause Patients With Erectile Dysfunction Unknown status NCT02943356 Phase 4 Tadalafil
2 Multi-Centre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
3 a Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial of Efficacy and Safety of Shu Gan yi Yang Capsule in the Treatment of Depression Associated With Erectile Dysfunction (Stagnation of Liver qi and Kidney Deficiency) Unknown status NCT03290313 Phase 4 shu gan yi yang capsule;shu gan yi yang capsule simulation agent
4 Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate i.m. 1000 mg. A Prospective, Multi-Center Clinical Study Phase IV. Unknown status NCT00555087 Phase 4 Testosterone Undecanoate and/or PDE-5
5 An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction. Unknown status NCT02225548 Phase 4 Selegiline;Tadalafil
6 Post-Prostatectomy Erectile Dysfunction: Effect of Hyperbaric Oxygen Therapy Unknown status NCT00906269 Phase 4 Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
7 Nebivolol Effects on Endothelial Function and Erectile Function in Non-smoking Pre-hypertensive and Newly Diagnosed Stage 1 Hypertensive Men With Erectile Dysfunction. Unknown status NCT01885988 Phase 4 Nebivolol;Sugar Pill
8 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
9 Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction: Non- Inferiority, Randomized, Crossover, Open Clinical Trial Unknown status NCT03169582 Phase 4 Avanafil;Sildenafil
10 A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy Unknown status NCT03142542 Phase 4 ZYDENA TAB.75mg(Udenafil 75mg);Placebo Oral Tablet
11 The Effect of Treatment for ED on Quality of Life and Satisfaction in a Group of Patients Without Prior Complaints of Sexual Dysfunction Unknown status NCT00313898 Phase 4 sildenafil (viagra)
12 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT01364701 Phase 4 Sildenafil 100 mg;Tadalafil 20 mg;Combination half of maximal dose for sildenafil & tadalafil
13 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
14 Assessment of Serum YKL-40 Level and Platelets Indices Among Patients With Diabetic Erectile Dysfunction Completed NCT05446493 Phase 4 Tadalafil 5mg
15 The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy in the Treatment of Men With Premature Ejaculation and Erectile Dysfunction (DAP-SPEED Study) Completed NCT02939495 Phase 4 Dapoxetine/Sildenafil 30/50 mg film coated tablet
16 Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are naïve to PDE5 Inhibitors Completed NCT01122264 Phase 4 Tadalafil;Sildenafil Citrate
17 Double-blind, Placebo Controlled, Randomized Study of Vardenafil to Determine Efficacy on Erectile Dysfunction (ED) in Men With ED and Metabolic Syndrome (ED-METABOLIC) Completed NCT00738400 Phase 4 Vardenafil (Levitra, BAY38-9456);Placebo
18 Effects of Continuous Subcutaneous Insulin Infusion (CSII) on Erectile Dysfunction in T2DM Patients: A Prospective, Exploratory, Controlled Trial Completed NCT01468519 Phase 4 Insulin
19 Oral Administration of L-Arginine in Patients With Erectile Dysfunction Completed NCT00777075 Phase 4 L-arginine;Placebo
20 A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men With Erectile Dysfunction Completed NCT01698684 Phase 4 Placebo;Avanafil 100 mg;Avanafil 200 mg
21 Efficacy and Safety of Lodenafil Carbonate in the Treatment of Erectile Dysfunction in Patient With Type II Diabetes. Multicentric Study. Completed NCT01180283 Phase 4 lodenafil carbonate
22 A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Viagra® (Sildenafil Citrate) on the PRN Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes Completed NCT00645268 Phase 4 sildenafil;placebo
23 A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate) In The United States Completed NCT00644631 Phase 4 sildenafil;placebo
24 Does Presence of Distress Due to Erectile Dysfunction Affect the Effect of Tadalafil on Sexual Life and Life Satisfaction? Completed NCT00547599 Phase 4 tadalafil
25 Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction (ED) Patients Previously Treated With Other Oral ED Therapy Completed NCT00422578 Phase 4 tadalafil
26 Phase IV Study of The Therapy of Long-acting Testosterone Undecanoate,1000mg in 4 ml Oily Solution for i.m.Injection(Nebido) as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction Completed NCT00421460 Phase 4 Testosterone Undecanoate,1000mg
27 Open Label, Multicenter, Non Comparative Study, To Confirm The Efficacy And Tolerability Of Viagra In Subjects With Erectile Dysfunction And Arterial Hypertension Who Are Taking Antihypertensive Treatment. Completed NCT00150358 Phase 4 Sildenafil Citrate
28 An Open-Label, Non-Comparative Study To Evaluate Treatment Responsiveness To The Quality Of Erection Questionnaire (QEQ) In Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate) Completed NCT00151463 Phase 4 sildenafil citrate
29 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study of Men With Mild to Moderate Erectile Dysfunction to Evaluate the Efficacy of Viagra 8 Hours Post-Dose Completed NCT00137072 Phase 4 Viagra (Sildenafil Citrate) 100 mg
30 Correlation of Flow Mediated Dilation of Brachial Artery and Carotid Intima Media Thickness With Erectile Dysfunction Severity and Clinical Response to PDE 5 Inhibitor in Hypertensive Men Completed NCT01084187 Phase 4 Vardenafil
31 A Randomised, Double-blind, Double-dummy, Parallel-group, Active-controlled Study Evaluating the Efficacy of Vardenafil Versus Tadalafil When Intercourse is Attempted Within 45 Minutes of Administration in Subjects With Erectile Dysfunction Completed NCT00663130 Phase 4 Levitra (Vardenafil, BAY38-9456);Tadalafil
32 Randomised, Double Blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Study to Evaluate the Efficacy and Tolerability of Vardenafil (BAY 38-9456) in Treatment of Male Erectile Dysfunction in Asia Completed NCT00668135 Phase 4 Vardenafil (Levitra, BAY38-9456);Placebo
33 Multi-centre, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Assess the Efficacy and Tolerability of Vardenafil and Its Influence on Self-esteem and Self Confidence in Subjects With Erectile Dysfunction. Completed NCT00665054 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
34 A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Viagra (Sildenafil Citrate) And Cialis (Tadalafil) Completed NCT00644956 Phase 4 tadalafil;sildenafil
35 Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Assessment of Treatment Preference Completed NCT00547352 Phase 4 tadalafil;sildenafil
36 A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Flexible-Dose Study To Assess The Efficacy And Safety Of Viagra (Sildenafil Citrate) In Men With Erectile Dysfunction (ED) Who Do Not Self Identify. Completed NCT00343200 Phase 4 Placebo;Viagra (sildenafil citrate)
37 A Prospective Multicenter, Parallel Group Study With A Single Blind Phase And A Double Blind Randomised Phase, To Evaluate The Efficacy And Satisfaction Of Viagra (Sildenafil Citrate) High Dose (100mg) Titration Compared With 50mg Dose, In Men With Erectile Dysfunction Completed NCT00249730 Phase 4 Sildenafil
38 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia Completed NCT00379756 Phase 4 LEVITRA (vardenafil);placebo
39 A Multi-Center, Flexible Dose Study With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Evaluate The Impact Of Treatment With Sildenafil Citrate On The Symptoms Of Depression And Quality Of Life (Qol) Of Male Patients With Erectile Dysfunction (ED) Completed NCT00159809 Phase 4 Viagra (Sildenafil citrate)
40 A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Prograf (Tacrolimus, FK 506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-sparing Radical Prostatectomy Completed NCT00106392 Phase 4 Tacrolimus;Placebo
41 Postmarketing Surveillance Study: A Randomized, Open-Label, 3-Month Interventional Study of Tadalafil Effectiveness (2.5 mg and 5 mg) and Long-Term Safety Administered Once Daily in Chinese Men With Erectile Dysfunction Completed NCT02224846 Phase 4 Tadalafil
42 A Randomized, Double Blind, Placebo Controlled, Flexible Dose, Multicentre Study of Levitra in a Broad Population of Men With Erectile Dysfunction and Previously Untreated With PDE5 Inhibitors. Completed NCT00668096 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
43 A Rand, db, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Plac in Men With Diabetes Mellitus Type 1 and Erectile Dysfunction Completed NCT00660998 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
44 An Open-label, Multi-center, Factorial Design, Cluster-randomized Clinical Study of Vardenafil in Canadian Males With Erectile Dysfunction: Impact of Education of the Primary Care Physician and Patient on Patient Outcomes. Completed NCT00664833 Phase 4
45 Multicenter, Double-Blind, Randomized, Placebo-controlled Study of Flexible, Titration Dose Administered on an As Needed Basis (PRN) to Evaluate the Efficacy and the Safety of Sildenafil for the Treatment of Erectile Dysfunction in Male Patients on Hemodialysis Completed NCT00654017 Phase 4 placebo;sildenafil
46 Androgen Modulation of Response to Selective Phosphodiesterase Inhibitors in Erectile Dysfunction Completed NCT00512707 Phase 4 Sildenafil citrate (open label);Testosterone gel
47 A Multicenter, Open Label, High Dose (100mg) Rapid Titration Study, To Evaluate The Efficacy And Satisfaction Of Patrex® (Sildenafil Citrate) In Men With Erectile Dysfunction In Mexico. Completed NCT00468650 Phase 4 sildenafil citrate
48 A Randomized, Double Blind, Parallel Group Study of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction and Their Female Partners Sexual Quality of Life. PARTNER II Completed NCT00377793 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
49 Multicenter Randomized Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose - II Completed NCT00143260 Phase 4 Viagra (Sildenafil Citrate) 100 mg
50 A Multicenter, Randomized, Parallel Group, Double-blind, Placebo-controlled Flexible Dose Study With and Open-label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States Completed NCT00143221 Phase 4 Viagra;Placebo

Search NIH Clinical Center for Impotence

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ginseng Preparation
Methyltestosterone
METHYLTESTOSTERONE PWDR
Papaverine
Papaverine Hydrochloride
yohimbine
Yohimbine hydrochloride

Genetic Tests for Impotence

Genetic tests related to Impotence:

# Genetic test Affiliating Genes
1 Erectile Dysfunction 28

Anatomical Context for Impotence

Organs/tissues related to Impotence:

MalaCards : Bone Marrow, Prostate, Spinal Cord, Smooth Muscle, Kidney, Endothelial, Bone

Publications for Impotence

Articles related to Impotence:

(show top 50) (show all 22385)
# Title Authors PMID Year
1
Epidemiological and clinical profiles of Saudi patients with hyperprolactinemia in a single tertiary care center. 62 41
36252148 2022
2
The Association Between FGF21 and Diabetic Erectile Dysfunction: Evidence from Clinical and Animal Studies. 62 41
36213282 2022
3
Evaluation of the quality of life of patients with premature ejaculation (lifelong and acquired). 41
36228262 2022
4
Toxicological evaluation of a dietary supplement formulated for male sexual health prior to market release. 53 62
20043970 2010
5
Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. 53 62
20402554 2010
6
T-786C polymorphism in promoter of eNOS gene as genetic risk factor in patients with erectile dysfunction in Turkish population. 53 62
19800665 2010
7
Adaptive spaced education improves learning efficiency: a randomized controlled trial. 53 62
20022032 2010
8
Increased cyclic guanosine monophosphate production and endothelial nitric oxide synthase level in mononuclear cells from sildenafil citrate-treated patients with erectile dysfunction. 53 62
19907424 2010
9
Pharmacotherapy for erectile dysfunction. 53 62
20092451 2010
10
Ten-year follow-up of sildenafil use in spinal cord-injured patients with erectile dysfunction. 53 62
19686427 2009
11
Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. 53 62
19884625 2009
12
[Efficacy and safety of tadalafil for erectile dysfunction: an updated review]. 53 62
20112748 2009
13
Is penile length a factor in treatment of erectile dysfunction with PDE-5 inhibitor? 53 62
19234311 2009
14
Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study. 53 62
19701217 2009
15
Association of coronary artery disease, erectile dysfunction, and endothelial nitric oxide synthase polymorphisms. 53 62
19466514 2009
16
Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. 53 62
19387454 2009
17
Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. 53 62
19377497 2009
18
Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients. 53 62
19210710 2009
19
EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor. 53 62
19036180 2009
20
In men with erectile dysfunction, satisfaction with quality of erections correlates with erection hardness, treatment satisfaction, and emotional well-being. 53 62
19143914 2009
21
[Psychosis and sexuality]. 53 62
19365914 2009
22
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. 53 62
19138360 2009
23
Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils. 53 62
19010346 2009
24
Online spaced education to teach urology to medical students: a multi-institutional randomized trial. 53 62
18614145 2009
25
PDE5 inhibitors in non-urological conditions. 53 62
19860698 2009
26
Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. 53 62
19125990 2009
27
Aspects of sexual satisfaction in men with erectile dysfunction: a factor analytic and logistic regression approach. 53 62
19170852 2009
28
[Tadalafil for erectile dysfunction: excellent safety and tolerance]. 53 62
19288756 2009
29
Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction. 53 62
18976905 2008
30
New treatments for localized prostate cancer. 53 62
19095127 2008
31
5-alpha reductase inhibitors and erectile dysfunction: the connection. 53 62
19090946 2008
32
The role of combination medical therapy in benign prostatic hyperplasia. 53 62
19002123 2008
33
Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction. 53 62
18528398 2008
34
Pulmonary embolism after tadalafil ingestion. 53 62
18548330 2008
35
Recreational use of PDE5 inhibitors by young healthy men: recognizing this issue among medical students. 53 62
18331258 2008
36
The effect of 5 alpha-reductase inhibitors on erectile function. 53 62
18421068 2008
37
[Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours]. 53 62
18998474 2008
38
Potent inhibition of human phosphodiesterase-5 by icariin derivatives. 53 62
18778098 2008
39
Safety of prescribing PDE-5 inhibitors via e-medicine vs traditional medicine. 53 62
18674473 2008
40
Gene therapy via inducible nitric oxide synthase: a tool for the treatment of a diverse range of pathological conditions. 53 62
18644193 2008
41
Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. 53 62
18395326 2008
42
Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial. 53 62
18423715 2008
43
A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. 53 62
18281145 2008
44
[Type V phosphodiesterase inhibitor erection-provoking test with audio-visual sexual stimulation for the diagnosis of erectile dysfunction]. 53 62
18572866 2008
45
[Expressions of eNOS and connexin 43 in the penile tissue of rats with diabetic erectile dysfunction]. 53 62
18572862 2008
46
Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction. 53 62
18385912 2008
47
The effect of physician and patient education when combined with vardenafil treatment in Canadian males with erectile dysfunction: an open-label, factorial-designed, cluster-randomized clinical trial. 53 62
18304285 2008
48
Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms. 53 62
18075506 2008
49
Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. 53 62
18086159 2008
50
Absence of hypogonadism in a male patient with a giant prolactinoma: a clinical paradox. 53 62
18082643 2008

Variations for Impotence

Expression for Impotence

Search GEO for disease gene expression data for Impotence.

Pathways for Impotence

Pathways related to Impotence according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1 13.56 ANGPT1 EDN1 EDNRA KLK3 KNG1 NOS3
2
Show member pathways
13.51 VEGFA TGFB1 NOS3 NOS2 NOS1 EDNRA
3
Show member pathways
13.15 VEGFA TGFB1 PDE5A NOS3 NOS2 NOS1
4
Show member pathways
12.82 VEGFA PRL NOS3 NOS2 NOS1 ANGPT1
5
Show member pathways
12.14 PDE5A NOS3 NOS2 NOS1 KCNMA1
6 11.83 VEGFA TGFB1 NOS2
7
Show member pathways
11.77 NOS3 NOS2 NOS1
8
Show member pathways
11.69 TGFB1 NOS3 NOS1 KNG1 CYP3A4 ACE
9 11.57 VEGFA NOS2 EDN1
10
Show member pathways
11.52 NOS3 NOS2 NOS1
11 11.48 VEGFA TGFB1 NOS2
12 11.47 EDN1 NOS3 VEGFA
13 11.46 ANGPT1 NOS3 VEGFA
14 11.45 NOS1 PDE3A PDE4A PDE5A
15 11.35 PDE3A NOS3 NOS2 NOS1
16
Show member pathways
11.3 NOS3 NOS2 NOS1
17 11.19 VEGFA NOS2 EDN1 ANGPT1
18 11.18 NOS3 EDNRA EDN1
19 11.05 NOS3 NOS2 NOS1
20
Show member pathways
10.99 PRL NOS3 NOS2 NOS1 EDNRA EDN1
21
Show member pathways
10.93 PDE5A NOS3 NOS2 NOS1 KCNMA1
22 10.79 VEGFA NOS1
23 10.67 PDE5A NOS3 NOS2 NOS1
24 10.59 VEGFA NOS3

GO Terms for Impotence

Cellular components related to Impotence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vesicle membrane GO:0012506 9.1 NOS3 NOS2 NOS1

Biological processes related to Impotence according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.38 ACE EDN1 NOS2 TGFB1 VEGFA
2 in utero embryonic development GO:0001701 10.31 VEGFA NOS3 EDNRA EDN1 ANGPT1
3 response to xenobiotic stimulus GO:0009410 10.25 TGFB1 SRD5A1 PDE3A EDN1 ACE
4 response to hormone GO:0009725 10.16 NOS3 NOS2 NOS1
5 response to lipopolysaccharide GO:0032496 10.16 ACE EDN1 NOS1 NOS2 NOS3
6 cell redox homeostasis GO:0045454 10.14 NOS3 NOS2 NOS1
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 10.14 VEGFA TGFB1 NOS1 ANGPT1
8 vasodilation GO:0042311 10.13 NOS3 NOS1 KNG1
9 regulation of blood pressure GO:0008217 10.13 NOS3 EDNRA EDN1 ACE
10 blood vessel remodeling GO:0001974 10.12 NOS3 EDNRA ACE
11 branching involved in blood vessel morphogenesis GO:0001569 10.09 VEGFA EDNRA EDN1
12 negative regulation of blood pressure GO:0045776 10.08 NOS3 NOS2 NOS1
13 positive regulation of MAP kinase activity GO:0043406 10.08 VEGFA TGFB1 PDE5A EDN1
14 nitric oxide biosynthetic process GO:0006809 10.02 NOS1 NOS2 NOS3
15 axonogenesis involved in innervation GO:0060385 10 EDNRA EDN1
16 negative regulation of hydrolase activity GO:0051346 10 NOS3 NOS1
17 vasoconstriction GO:0042310 10 ACE EDN1 EDNRA
18 regulation of glucose transmembrane transport GO:0010827 9.99 EDNRA EDN1
19 noradrenergic neuron differentiation GO:0003357 9.99 EDNRA EDN1
20 cardiac neural crest cell migration involved in outflow tract morphogenesis GO:0003253 9.99 EDNRA EDN1
21 nitric oxide mediated signal transduction GO:0007263 9.99 NOS3 NOS2 NOS1
22 cellular response to luteinizing hormone stimulus GO:0071373 9.98 EDNRA EDN1
23 body fluid secretion GO:0007589 9.97 VIP EDN1
24 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.97 NOS3 EDN1
25 peptidyl-cysteine S-nitrosylation GO:0018119 9.96 NOS1 NOS2
26 sympathetic neuron axon guidance GO:0097492 9.94 EDNRA EDN1
27 neural crest cell fate commitment GO:0014034 9.94 EDNRA EDN1
28 regulation of nitric oxide mediated signal transduction GO:0010749 9.93 PDE5A VEGFA
29 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.92 ACE VEGFA
30 positive regulation of guanylate cyclase activity GO:0031284 9.91 NOS3 NOS2 NOS1
31 positive regulation of blood vessel endothelial cell migration GO:0043536 9.91 VEGFA TGFB1 NOS3 ANGPT1
32 endothelin receptor signaling pathway involved in heart process GO:0086101 9.9 EDN1 EDNRA
33 regulation of sodium ion transport GO:0002028 9.89 TGFB1 NOS3 NOS1
34 cellular response to human chorionic gonadotropin stimulus GO:0044751 9.88 EDN1 EDNRA
35 positive regulation of oocyte development GO:0060282 9.87 PDE3A PDE5A
36 meiotic cell cycle process involved in oocyte maturation GO:1903537 9.86 EDN1 EDNRA
37 response to laminar fluid shear stress GO:0034616 9.85 TGFB1 ACE
38 response to salt GO:1902074 9.84 TGFB1 EDN1
39 positive regulation of odontogenesis GO:0042482 9.8 EDN1 TGFB1
40 positive regulation of vascular permeability GO:0043117 9.8 VEGFA TGFB1 PDE3A
41 negative regulation of potassium ion transport GO:0043267 9.8 VIP NOS3 NOS1
42 mononuclear cell proliferation GO:0032943 9.65 TGFB1 ACE
43 arginine catabolic process GO:0006527 9.63 NOS3 NOS2 NOS1
44 response to hypoxia GO:0001666 9.47 VEGFA TGFB1 NOS2 NOS1 KCNMA1 EDNRA
45 cellular biosynthetic process GO:0044249 9.43 NOS1 NOS2 NOS3
46 blood vessel diameter maintenance GO:0097746 9.43 NOS3 KNG1 EDN1 ACE

Molecular functions related to Impotence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 10.06 NOS3 NOS2 NOS1 CYP3A4
2 NADP binding GO:0050661 9.88 NOS3 NOS2 NOS1
3 3',5'-cyclic-nucleotide phosphodiesterase activity GO:0004114 9.8 PDE3A PDE4A PDE5A
4 cadmium ion binding GO:0046870 9.73 NOS3 NOS1
5 FMN binding GO:0010181 9.73 NOS3 NOS2 NOS1
6 arginine binding GO:0034618 9.63 NOS3 NOS2 NOS1
7 phosphoric diester hydrolase activity GO:0008081 9.54 PDE5A PDE4A PDE3A
8 tetrahydrobiopterin binding GO:0034617 9.43 NOS3 NOS2 NOS1
9 nitric-oxide synthase activity GO:0004517 9.1 NOS3 NOS2 NOS1

Sources for Impotence

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....